CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
Atorvastatin +1 moredrug
Likely dose
Atorvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03308578
NCT03308578Phase 2Completed
CompareCT.gov

Statins and CPAP in Adipose Tissue: A Randomized Clinical Trial in Obstructive Sleep Apnea

Mayo Clinic·interventional·Posted Oct 12, 2017·Updated Dec 16, 2024

In Brief

A Phase 2 clinical trial evaluating Atorvastatin and Placebo oral capsule for Sleep Apnea, Obstructive. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This study is aimed at examining the alterations in adipose tissue in obstructive sleep apnea (OSA) patients in response to treatment with atorvastatin in continuation with standard treatment with continuous positive airway pressure (CPAP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Apnea, Obstructive
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 12, 2017
Enrollment StartJan 8, 2018
Primary CompletionDec 12, 2023
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 8.7 years ago

Interventions

Atorvastatindrug

Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study

Placebo oral capsuledrug

Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study